Pharmacologic safety of oral ivermectin in pregnant women

Authors

  • Carlos Esquén Leyva Gynecologist and Obstetrician, Assistant Physician, Hospital Belén de Trujillo, La Libertad, Peru
  • Humberto Hashimoto Pacheco Gynecologist and Obstetrician, Assistant Physician, Hospital Belén de Trujillo, La Libertad, Peru

DOI:

https://doi.org/10.31403/rpgo.v66i2285

Keywords:

Ivermectin, Patient safety, Pregnancy

Abstract

This study was intended to determine the pharmacological safety of oral ivermectin in pregnant women. A systematic review of information published in the PubMed, MEDLINE, Scopus, Toxline, World Health Organization Clinical Trials Registry, US FDA List, ClinicalTrials, and Cochrane Central Registry databases was conducted from 1990 through 2020. From a total of 73 research articles reviewed, two animal experiments, one clinical and five analytical experiments were studied. Animal studies were found to show that ivermectin was associated with the risk of micarriage, congenital malformations, stillbirth and maternal death. In humans, the effects presented in the animal study could not be determined. It is concluded that clinical studies are necessary to establish the presence of adverse effects in pregnant women from the consumption of ivermectin.

Downloads

Download data is not yet available.

Published

2020-12-03

How to Cite

Esquén Leyva, C., & Hashimoto Pacheco, H. (2020). Pharmacologic safety of oral ivermectin in pregnant women. The Peruvian Journal of Gynecology and Obstetrics, 66(4). https://doi.org/10.31403/rpgo.v66i2285

Issue

Section

Revisión Sistemática

Similar Articles

You may also start an advanced similarity search for this article.